Citi analyst Yigal Nochomovitz lowered the firm’s price target on Rain Oncology to $24 from $29 and keeps a Buy rating on the shares. The analyst updated the model to reflect the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RAIN:
- Rain Oncology price target lowered to $17 from $18 at Mizuho
- Rain Oncology price target raised to $19 from $12 at H.C. Wainwright
- Rain Oncology reports Q4 EPS (70c), consensus (56c)
- Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks